We screened the RAD51, XRCC3, and XRCC2 genes for germline variation in familial BRCA1/2-negative breast or ovarian cancer patients in order to evaluate the role of these genes in breast cancer predisposition in Finland and to identify putative recurrent founder mutations. This evidence concerns the gene RAD51 and breast carcinoma.